Investors and Media

Idera Pharmaceuticals is a biopharmaceutical company focused on the acquisition, development and ultimate commercialization of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Furthering our commitment to this goal, in September 2022 Idera merged with Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonology and rheumatology diseases that typically have no treatment. To learn more about Aceragen, visit

Featured Presentation
More information is coming soon.


There are currently no events to display.


There are currently no events to display.

Data Provided by Refinitiv. Minimum 15 minutes delayed.